Hematopoietic stem cell (HSC) gene therapy is a demonstrated effective treatment for X-linked severe combined immunodeficiency (SCID-X1), but B-cell reconstitution and function has been deficient in many of the gene therapy treated patients. Cytoreductive preconditioning is known to improve HSC engraftment, but in general it is not considered for SCID-X1 since the poor health of most of these patients at diagnosis and the risk of toxicity preclude the conditioning used in standard bone marrow stem cell transplantation. We hypothesized that mobilization of HSC by granulocyte colony-stimulating factor (G-CSF) should create temporary space in bone marrow niches to improve engraftment and thereby B-cell reconstitution. In the present pilot study supplementing our earlier preclinical evaluation (Huston et al., 2011), Il2rg<sup>-/-</sup>mice pretreated with G-CSF were transplanted with wild-type lineage negative (Lin<sup>-</sup>) cells or Il2rg<sup>-/-</sup>Lin<sup>-</sup>cells transduced with therapeutic IL2RG lentiviral vectors. Mice were monitored for reconstitution of lymphocyte populations, level of donor cell chimerism, and antibody responses as compared to 2Gy total body irradiation (TBI), previously found effective in promoting B-cell reconstitution. The results demonstrate that G-CSF promotes B-cell reconstitution similar to low-dose TBI and provides proof of principle for an alternative approach to improve efficacy of gene therapy in SCID patients without adverse effects associated with cytoreductive conditioning.

doi.org/10.1089/hum.2014.101, hdl.handle.net/1765/91825
Human Gene Therapy
Erasmus University Rotterdam

Huston, M.W, Riegman, A.R.A, Yadak, R.M.A, van Helsdingen, Y.M, De Boer, H, van Til, N.P, & Wagemaker, G. (2014). Pretransplant mobilization with granulocyte colony-stimulating factor improves b-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice. Human Gene Therapy, 25(10), 905–914. doi:10.1089/hum.2014.101